Katano M, Yamamoto H, Matsunaga H, Mori M, Takata K, Nakamura M
Dept. of Surgery, Saga Medical School.
Gan To Kagaku Ryoho. 1990 May;17(5):1045-9.
A new type of cell growth inhibitory substance was isolated and purified from a powder of the root of Panax ginseng C.A. Meyer, which has been commonly used for the treatment of various disease as a commercial medical drug by the name of Korean Red Ginseng Powder. Data from the infrared spectra, proton and carbon-13 nuclear magnetic resonance, and high resolution mass spectra were identical with those of authentic panaxytriol. Cell growth inhibition by panaxytriol seemed to be tumor-specific. Its action was supposed to be more dose-dependent than time-dependent. In vivo antitumor efficacy of panaxytriol was tested against C57BL/6 mice transplanted with B 16 melanomas. Panaxytriol (40 mg/kg) administered intramuscularly produced significant tumor growth delays in mice (p less than 0.01).
从人参（Panax ginseng C.A. Meyer）根粉中分离并纯化出一种新型细胞生长抑制物质，人参根粉作为一种商业药物，通常以韩国红参粉之名用于治疗各种疾病。红外光谱、质子和碳-13核磁共振以及高分辨率质谱数据与正品人参三醇的数据一致。人参三醇对细胞生长的抑制似乎具有肿瘤特异性。其作用被认为更多地依赖于剂量而非时间。在移植了B16黑色素瘤的C57BL/6小鼠身上测试了人参三醇的体内抗肿瘤功效。肌肉注射给予人参三醇（40毫克/千克）可显著延迟小鼠肿瘤生长（p小于0.01）。
